China, Hong Kong stocks rebound after steep weekly loss
HONG KONG : Chinese and Hong Kong stocks inched higher today, recovering from last week's sharp declines, as defense and banking stocks led gains.
By the midday break, the Shanghai Composite index was up 0.2% at 3,567.02 points, recovering from losses in the opening hour.
The blue-chip CSI300 index was barely changed.
The defence sector led the onshore market higher with a 2.2% gain.
The banking sector added 1% and semiconductors gained 0.4%.
The small gains today came after markets booked their steepest losses since April last week.
The bullish trend for Chinese equities has started to show signs of slowing as the much anticipated Politburo meeting and tariff negotiations with the US both failed to deliver positive surprises.
'Market sentiment is becoming more volatile as positive catalysts are losing momentum,' Citic Securities said in a note, adding that investors might shift focus to defensive sectors and those more insulated from external shocks.
In Hong Kong, the benchmark Hang Seng Index was up 0.5% at 24,627.25, also recovering from last week's loss.
The tech sector jumped 0.9% and AI-related shares added 1%, leading markets higher.
Looking ahead, markets are awaiting new developments on the trade truce between China and the US that expires on Aug 12.
US treasury secretary Scott Bessent said on Friday that Washington has the makings of a deal and was 'optimistic' about the path forward.
China's trade data and CPI readings later this week will also give investors more clues about the health of the world's second-largest economy.
'Given rising uncertainties in the foreign market, especially in the US where Trump's intervention of economic reporting undermines the efficacy of policies, both on- and off-shore Chinese markets will likely be under pressure in the near term,' Hong Hao, CIO at Lotus Asset Management, said in a note.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
2 hours ago
- Malay Mail
Yuexiu Transport (1052) profit attributable to shareholders increased by 15%
HONG KONG SAR - Media OutReach Newswire - 15 August 2025 - Yuexiu Transport (1052) announced its interim results 2025 and recorded revenue of RMB2.099 billion, representing a year-on-year increase of 14.9%. Profit attributable to shareholders was RMB361 million, an increase of 14.9%. The Company remains committed to maintaining a stable dividend policy with an interim dividend of HK$0.12 per share, equivalent to the payout ratio of 50%.In November 2024, the Company acquired the Pinglin Expressway from its parent company. During the period, this project contributed approximately RMB256 million in toll revenue and approximately RMB42 million in profit attributable. This project is continuously bringing new momentum to the Company's development and benefiting its long-term the first half of 2025, the Company's revenue and profit attributable to shareholders both realized double-digit growth. The Company's 10 subsidiary projects, as a whole, recorded y-o-y growth in both average daily toll revenue and average daily toll traffic volume. The Company further reduced its total liabilities-to-total assets ratio, continued to optimise its financial structure and further extended its debt duration. The total liabilities-to-total assets ratio was 57.9%, dropped by 1.0 percentage point compared to the end of 2024. The weighted average financing rate was 2.57%, down by 0.48 percentage point compared to the first half of Company is committed to becoming a leading transport infrastructure asset management company in China. Guided by its "3331" development strategy, the Company will refine the three platforms (listed platform, REITs platform, incubation platform), enhance the three core abilities (investment ability, operation and maintenance and construction management ability, capital operation ability), and focus on three directions (expressway main business, key areas, expansion of related auxiliary businesses).The Company will firmly grasp the strategic opportunities in expressway investment and mergers and acquisitions. Gaining its foothold in Guangdong, Hong Kong and Macau Greater Bay Area and in Central and Eastern China, the Company will expand its presence in the regions benefiting from urbanisation process and rapid industrialisation development. With the full utilisation of a model that features interaction among its three platforms, the Group continues to strengthen and expand its infrastructure business, with a particular focus on toll #YuexiuTransport The issuer is solely responsible for the content of this announcement.
BusinessToday
3 hours ago
- BusinessToday
Private Healthcare Sector Faces Rising Medical Inflation Pressures, CIMB
Malaysia's private healthcare sector is grappling with rising medical inflation and potential structural changes as discussions advance on the adoption of a diagnosis-related group (DRG)–based hospital payment system, according to insights from a recent meeting between CIMB Securities and Datuk Dr Kuljit Singh, President of the Association of Private Hospitals Malaysia (APHM). Private hospitals currently cater to about 30% of Malaysia's patient load—funded primarily through self-payment, personal insurance, and employee benefits—while the public sector supports the remaining 70%. Dr Kuljit highlighted that Malaysia's healthcare quality remains on par with, or better than, many ASEAN peers, sustaining the nation's appeal as a medical tourism hub. Medical Inflation Above Global Average Bank Negara Malaysia (BNM) data shows that medical inflation hit 15% in 2024, surpassing the global average of 10% and the Asia-Pacific average of 11%. Key cost drivers include the adoption of advanced medical technologies, rising medical supply costs, manpower shortages, and overall inflationary pressures. Between 2021 and 2023, claims in the Medical and Health Insurance/Takaful (MHIT) segment surged 73%, outstripping the 21% growth in premiums. Claim frequency more than doubled to 25 per 100 policyholders in 2023 from 11 in 2018. In response, BNM has capped annual premium increases at 10% until the end of 2026, with hikes staggered over three years. Dr Kuljit cautioned that prolonged premium caps could prompt insurers to tighten reimbursement terms and limit hospital or treatment options, potentially curbing investment in private healthcare. To mitigate rising claims, private hospitals are offering negotiated discounts to insurers, which in turn lower out-of-pocket costs for insured patients compared with self-paying patients. Exploring DRG to Curb Costs The proposed DRG system would replace the traditional fee-for-service model with fixed prices for treatments based on case complexity and industry benchmarks. APHM is working with the Ministry of Health to collect and standardise data for a private healthcare DRG database. However, implementation challenges remain due to the lack of a universal healthcare financing framework and comprehensive private-sector data. Globally, DRG models are largely confined to public healthcare systems, with limited adoption in private healthcare. Dr Kuljit noted that complications or additional care beyond the DRG package often create billing and coverage issues in private settings. Sector Outlook CIMB Securities noted that KPJ Healthcare Bhd could be more exposed to DRG-related risks, with 98.1% of its revenue derived locally in 1Q25, compared with IHH Healthcare Bhd's 18–21% Malaysian revenue contribution. The brokerage maintains an Overweight stance on Malaysia's healthcare sector, citing its defensive nature, resilient demand, organic expansion, and favourable demographics. IHH remains its top pick with a Buy rating and a target price of RM8.50, trading at attractive valuations relative to historical and regional averages. KPJ is rated Hold with a TP of RM2.90, as its current share price is seen to have priced in recent operational improvements.
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Swiss economy unexpectedly expanded before 39% tariff hit
SWITZERLAND'S economy unexpectedly grew in the second quarter, maintaining some momentum before the country was hit with one of the highest US tariff rates. The expansion of 0.1% was better than the contraction of 0.1% forecast by economists in a Bloomberg survey. It follows a 0.8% pace in the previous three months, a growth spurt driven by exporters front-loading sales to the US before trade levies kicked in. The positive figures come as the country digests US President Donald Trump's imposition of a painful 39% tariff on Switzerland — the steepest among developed nations. Despite that rate, analysts are optimistic that a recession can be avoided. The Swiss government is still negotiating to try to secure a lower level. Treasury Secretary Scott Bessent has said the US aims to largely wrap up talks with countries that haven't secured a trade deal by the end of October. Swiss officials see this as a hopeful signal that they have a chance to get better terms by then. The figures published Friday, which are adjusted for large sports events, are an initial estimate. The State Secretariat for Economic Affairs said a 'negative performance in industry has been counterbalanced by gains in the services sector.' A separate Bloomberg survey this week predicted that the Swiss economy will grow 1.4% this year — outpacing the euro zone — assuming a lower levy can still be hammered out with Washington and the key pharmaceutical industry escapes significant surcharges. The Swiss government is similarly bullish, maintaining its June prediction for expansion that's roughly in line with the consensus. It did at that time, however, also publish a negative scenario with growth of just 0.8%. Some companies are assessing whether to move some production outside Switzerland to avoid the latest tariffs. Medicines — currently exempt from tariffs — are a large unknown after Trump warned that he plans to announce measures on the sector. Pharma giants Roche Holding AG and Novartis AG discussed the situation Thursday with the Swiss government. 'With a 39% tariff also on pharmaceuticals and pressure on drug prices in the US, two negative effects would combine, leading to a significant slowdown in GDP growth in Switzerland,' Hans Gersbach, co-head of Zurich's KOF research institute, said this week. 'A risk of recession could then not be ruled out.' Friday's data strip out big sports events as they can distort the overall picture of the Swiss economy. The country is home to many global sports bodies, meaning that when, for instance, the Olympic Games take place — earning revenue for the International Olympic Committee — Swiss GDP gets a boost without economic activity benefiting. A final reading is due on Aug. 28. –BLOOMBERG
